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Objective: To characterize pain-related behavior during the course of knee osteoarthritis (OA) induced by
destabilization of the medial meniscus (DMM) in wild type (WT) and in ADAMTS-5 null mice.
Methods: DMM surgery was performed in the right knee of CD-1 mice. At regular intervals up to 8 weeks
after surgery, mice were assessed for the following parameters: mechanical allodynia (via withdrawal
thresholds to von Frey ﬁlaments applied to the plantar surface of both hind paws or to the tail), thermal
hyperalgesia, locomotor activity and gait analysis. In addition, mechanical allodynia was tested in
C57BL/6 WT or ADAMTS-5 null mice following DMM surgery.
Results: In CD-1 mice, a robust and progressive decrease in withdrawal threshold was observed in both
hind paws after DMM but not sham surgery. Allodynia was apparent as early as 14 days postoperatively.
Both sexes developed OA changes after surgery with concurrent mechanical allodynia. No other pain-
related behavioral changes were detected up to 8 weeks post-surgery. In C57BL/6 mice, a genetic
background in which only males develop OA changes after DMM, males but not females developed
allodynia in the ipsilateral hind paw. In contrast, C57BL/6 ADAMTS-5 null mice did not develop OA
changes or mechanical allodynia up to 8 weeks post-surgery.
Conclusion: Joint pathology following DMM surgery in mice is associated with progressive mechanical
allodynia. ADAMTS-5 null mice are resistant to DMM-induced OA-like lesions and to the associated
mechanical allodynia.
 2010 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Pain is the major symptom in osteoarthritis (OA) and contrib-
utes to impaired function and loss of quality of life. Pain related to
knee OA is the leading cause of impaired mobility in the elderly
population in the US1. Available therapies include non steroidal
anti-inﬂammatory drugs (NSAIDs), viscosupplementation, or
steroids, all of which can alleviatemild-to-moderate pain in OA, but
relief from severe chronic OA pain remains an unmet medical need
and a major reason for seeking surgical intervention. A recent
overview in Arthritis and Rheumatism cited OA pain as the most
common reason for undergoing hip or knee replacement, with
a w50% increase in the number of surgeries performed in the US
between 2000 and 2004 and a projection of 600,000 hip and 1.4
million knee replacements in the year 20152.: Anne-Marie Malfait, Rush
n Building, 5th Floor, 1735W.
3-2961.
M. Malfait).
Elsevier Ltd on behalf of OsteoarthOA pathology is characterized by changes in all joint tissues,
including focal cartilage degeneration, synovial changes, sub-
chondral bone sclerosis, bone cysts, and osteophyte formation. The
past decade has brought major advances in our understanding of
mechanisms involved in structural joint damage,whichhas led to the
identiﬁcation of potential therapeutic targets, including targets in
pathways of cartilage degradation, bone turnover, and inﬂammation.
Notably, the aggrecanases, ADAMTS-4 and ADAMTS-5 (A Disintegrin
and Metalloproteinase with Thrombospondin Motif), have emerged
as key players in joint tissue damage3. Blockade of aggrecanases
through pharmacological agents or siRNA prevents cartilage degra-
dation in vitro4–6 and in vivo7. Studies in genetically modiﬁed mice
have convincingly demonstrated that ADAMTS-5 ablation protects
against the entire joint pathology (cartilage lesion formation, sub-
chondral bone changes, osteophytosis)8,9 and might even promote
repair10 (and Plaas et al., submitted). Therefore, ADAMTS-5 emerges
as a key target for development of disease-modifying drugs for OA
(DMOADs). In fact,Wyeth has just completed a phase I studywith an
aggrecanase inhibitor (http://clinicaltrials.gov). However, it remains
unclear to which extent successful disease modiﬁcation (i.e., haltingritis Research Society International.
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patient through reducing pain. Generally, there is no simple rela-
tionship between severity of joint pathology and the accompanying
clinical symptoms. Several studies suggest a lack of correlation
betweenradiographic changesandtheseverityofpain, so thatpeople
with radiographic changesmay have no pain at all while peoplewith
pain may have only mild radiographic changes11. Nonetheless,
a causal relationship between OA changes and pain should be
assumed, and it has been shown that radiographic evidence of joint
damage predisposes to pain12. A recent study reported that, when
usingmethods thatminimize between-person confounding, a strong
structure–symptom association exists in OA of the knee13.
No animal models adequately describe the correlation between
joint structure and symptoms, and very few animal studies have
properly examined mechanisms of acute and chronic pain in OA.
Inﬂammatory assays commonly used by pain researchers mostly
involve injection of mediators such as formalin or carrageenan into
the footpad, with highly questionable relevance to OA14.
Conversely, traditional models of OA focus almost exclusively on
joint damage without attempting to study pain. Thus, few reports
exist that have attempted to integrate the two areas of research.
Rodentmodels that have been used to study OA pain includemono-
iodo acetate (MIA) injection into rat knees15 and the rat medial
meniscal tear (MMT) model16. A recent paper discusses the murine
destabilization of the medial meniscus (DMM) model for the study
of OA-related pain17. This model offers the advantage that, unlike in
traditional rodent models, the joint pathology after DMM surgery
progresses slowly and in clearly deﬁned stages over 16 weeks17,18.
Using this model, Inglis et al.17 reported that potential signs of pain
appeared well after the onset of severe joint damage. Joint lesions
were clearly established by 4–8 weeks after surgery, while
parameters such as changes in weight distribution and in sponta-
neous activity were not apparent until 8–10 weeks post-surgery.
It remains, however, controversial whether staticweight bearing
and hypolocomotion are valid dependent measures of pain in the
mouse (Mogil et al., submitted). Furthermore, a model where
behavioral changes appear earlier after surgery would offer a prac-
tical advantage. The protracted nature of the DMMmodel uniquely
allows for studying the early stages of the pathology and assessing
whether any pain-relatedmeasures can be detected. The goal of the
current study was two-fold: 1) to develop a sensitive, reproducible
pain assessment in the mouse with early DMM-induced OA; and 2)
to determine the effect of ADAMTS-5 deﬁciency on pain.
Materials and methods
Subjects
Subjects were naı¨ve, adult mice of both sexes19, either outbred
CD-1 mice (ICR:Crl; Charles River, Boucherville, QC) or wild type
(WT) and Adamts5 null mutant (knockout; KO)mice, maintained on
a congenic C57BL/6J background. Mice were housed in standard
shoebox cages of 2–4 same-sex littermates in a temperature-
controlled (201C) environment (14 h:10 h light/dark cycle;
lights on at 07:00 h), with ad lib access to food (Harlan Teklad 8604)
and tap water. Adamts5 KO and WT mice were housed with same-
sex mice of the same genotype for at least 1 week before testing. All
experiments occurred in the light (resting) phase (30 lux ﬂuores-
cent room lighting); mice were habituated to the testing room for
2 h before testing.
Generation of Adamts5 KO mice
The Adamts5 conditional KO model was generated in collabo-
ration with Lexicon Genetics (The Woodlands, TX) on a 129S5(formerly, 129/SvEvBrd) background20. Exon 2 of the Adamts5 gene
was targeted because it encodes part of the zinc binding domain
that is necessary for proteolytic activity. The targeting constructwas
built such that exon 2 was ﬂanked by loxP sites and upon successful
homologous recombination in embryonic stem (ES) cells creates
the targeted allele [Fig. 1(a)]. To excise the phosphoglycerine kinase
promoter driving neomycin resistance gene expression (PGK–NEO)
selectionmarker, targetedmicewere bred to the ROSA26 promoter-
driving Flipper recombinase mouse model on a C57BL/6J back-
ground21. To convert the targeted or neomycin cassette-excised (NE)
model into a conventional KO, they were bred with EIIa-cre (on
a mixed FVB/N and C57BL/6 background)22 to delete exon 2 in the
Adamts5 genomic locus [Fig. 1(a)]. Exon 2 (133 base pairs (bp))
encodes the N-terminal part of the protease consensus sequence,
HEIGH. Its deletion is expected to create a frameshift for down-
stream coding sequences. Three targeted ES clones were identiﬁed
from screening 300 clones [Fig. 1(b)] and found to have retained
their 50 loxP site as examined with an internal Southern blot and
a Southern blot detecting for absence of random neomycin cassette
integration into the genome (not shown). These were carried along
to generate the targetedmodel.When converting the targeted toNE
or KO alleles, we observed that neither ROSA26-FLP nor EIIa-cre
excision was 100% penetrant, as evident in the example of EIIa-cre
excision of the Adamts5 ﬂoxed allele by the coexistence of WT, NE
and KO alleles in a single mouse [Fig. 1(c)]. Thus, mice mosaic for
these alleles were bred further to segregate the different alleles into
different lineages. At the time of use, the model had been back-
crossed to C57BL/6J for over eight generations, yielding on average
99.61% C57BL/6J, with a small portion carried over from 129S5 from
the ES cells and possibly FVB/N from the EIIa-cre model. Initial
screening for targeted ES clones was performed with a Southern
blot with BglII restriction digestion of genomic DNA isolated from
tail snips and detected with a 30 external probe [Fig. 1(a, b)]. In this
strategy, the WT fragment is 3.84 kb and the targeted fragment
5.8 kb. Genotyping of the mouse colony was performed by poly-
merase chain reaction (PCR) with the forward primer 45, 50-TTT
GAA TTT GTC TTT GGA AGG CCT C-30 and the reverse primer 24,
50GAC AGT GTT GAC TCA TCC GGG GAT A-30 [Fig. 1(a, c)]. In this
strategy, the WT amplicon is 642 bp, targeted allele 2632 bp, NE
allele 903 bp, and KO fragment 374 bp.
Medial meniscal destabilization
DMM was performed in 8–12-week old mice of both sexes,
based on the described method23, with a slight modiﬁcation to
ensure patellar luxation by bending the knee. In brief, after medial
parapatellar arthrotomy, the patella was laterally luxated. The
anterior fat pad was dissected to expose the anterior medial
meniscotibial ligament, which was severed. The patella was repo-
sitioned, the knee ﬂushed with saline and the incision closed.
Surgery was performed in the right knee only. Sham surgery, per-
formed in age and sex-matched mice, was identical to DMM except
that the medial meniscus remained intact. Mice were housed, 2–4
per cage, for speciﬁed periods up to 56 days post-surgery. At
necropsy, knee joints were trimmed of muscle and collected in 10%
neutral buffered formalin for histology.
Histology
Femoral tibial joints were formalin ﬁxed, decalciﬁed using
Immunocal (Decal Chemical Corporation, Congers, NY), and
parafﬁn-embedded. Joints were step-sectioned in the sagittal plane
starting on the medial aspect. Step sections were 4 mm thick,
stained with toluidine blue, numbered sequentially and collected
throughout the joint.
Fig. 1. Schematic representation of the generation of ADAMTS-5 null mice. (a) The targeting vector was constructed with loxP sites (triangles) ﬂanking exon 2 which, upon
successful homologous recombination in ES cells, would be incorporated into the Adamts5 locus (targeted allele). When exposed to cre recombinase, sequences encompassed
between the 2 loxP sites will be excised and the targeted allele converted to a KO allele. Black horizontal bar: linear genomic sequence of the ADAMTS-5 gene; ﬁlled box: exon;
triangle: loxP site; diamond: ﬂippase recognition target (FRT) site; box labeled NEO: PGK/NEO selection marker cassette; arrows: forward and reverse primers used in a PCR reaction
for genotyping; small black box: location of sequence used as a probe in the 30 external Southern blot. Thin horizontal bar maps sizes of the Bg1II restriction fragment lengths
predicted in a Southern blot for each of the WT, targeted and KO alleles; (b) Southern blot analysis with Bg1II restriction digestion and detected with the 30 external probe marked in
Fig. 1(a) identiﬁed three ES clones (3A1, 3A12 and 4A12) successfully targeted at the 30 homology arm region of the Adamts5 locus. In this scheme, the WT fragment is 3.84 kb and
the targeted 5.8 kb. Right hand panel shows the DNA molecular weight (MW) marker with bands corresponding to 4, 5 and 6 kbs; (c) Agarose gel electrophoresis of PCR products
from PCR reaction suggesting presence or absence of the different ADAMTS-5 alleles using the forward and reverse primer pairs (45 and 24) depicted in Fig. 1(a). Left hand lane
shows the DNA MW marker with bands corresponding to 500 and 1000 bp.
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Mice were tested using the up–down staircase method of
Dixon24. Mice were placed on a perforated metal ﬂoor (with 5-mm
diameter holes placed 7 mm apart) within small Plexiglas cubicles
(9 5 5 cm high), and a set of eight calibrated von Frey ﬁbers
(Stoelting Touch Test Sensory Evaluator Kit #2 to #9; ranging from
z0.015 g toz1.3 g of force) were applied to the plantar surface of
the hind paw until the ﬁbers bowed, and then held for 3 s. The
threshold force required to elicit withdrawal of the paw (median
50% withdrawal) was determined twice on each hind paw (and
averaged) on each testing day, with sequential measurements
separated by at least 5 min. In one experiment, the von Frey ﬁberswere aimed at the mid-ventral tail instead of the hind paw. For all
sites, baseline (BL) thresholds were assessed 1 and 2 weeks prior
to surgery, and at 2-week intervals post-surgery (day 14, 28, 42,
and 56).
Radiant heat paw-withdrawal test
Mice were placed on a 3/16th-inch thick glass ﬂoor within
Plexiglas cubicles as described above, and a focused high-intensity
projector lamp beam was shone from below onto the mid-plantar
surface of the hind paw25. The commercial device (IITC Model 336)
was set to 20% active intensity. Latency to withdraw from the
stimulus was measured to the nearest 0.1 s. On each testing day,
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separated by at least 30 min, for a grand total of eight latency
measurements per hind paw, which were averaged.
Locomotor activity
Some mice were tested for overnight locomotor activity in their
home cages, but with the wire cage top replaced with a clear
Plexiglas sheet (to prevent hanging behavior that confuses the
software); food and water were unavailable. Mice (n¼ 10/sex) in
this experiment were housed singly for the entire duration of the
longitudinal experiment (56 days). For the overnight locomotor
activity testing, their home cage was placed on a table top within
a photocell-based commercial apparatus (Opto-Varimex Micro
Animal Activity System; Columbus Instruments; Columbus, OH),
capable of measuring horizontal (walking) and vertical (rearing)
locomotion simultaneously in four cages. To reduce ﬂoor-effect
confounds on locomotor activity, mice were tested for 6 h starting
just after lights-off (19.00 h), at the start of their active phase.
CatWalk dynamic gait analysis
The CatWalk system (Noldus Inc.) of automated gait analysis
has been described in detail previously26. Subjects traverse
awalkway (109 cm long; 8 cmwide) with a glass ﬂoor in a darkened
room. Light enters the distal long edge of the glass ﬂoor from
a ﬂuorescent bulb located at the side, and is internally reﬂected,
scattering only at points where a paw touches the glass, producing
bright illumination of the contact area. A video camera monitors the
corridor, and the digitized signal is stored for later analysis of the
‘‘videotapes’’ of animals crossing the walkway. A number of ‘‘single
paw’’ and interlimb coordination parameters can be obtained from
the software; we have previously foundmean intensity (the average
intensity of the pixels at the maximum paw-ﬂoor contact) to be the
most reliable in the mouse for the measurement of gait changes
after neuropathic injury (Mogil et al., submitted).
Drugs
The anti-allodynic effects of morphine and acetaminophenwere
evaluated. Morphine (Sandoz Canada, Boucherville, QC) was
administered subcutaneously (10 mL/kg; in physiological saline) at
10 mg/kg. Acetaminophen (Sigma, St. Louis, MO) was administered
subcutaneously (10 mL/kg; in polyethylene glycol) at a dose of
250 mg/kg. Doses were based on previous experiencewithmultiple
pain states in the laboratory mouse27,28.Fig. 2. Withdrawal thresholds in the hind paw, measured by von Frey as described in Mat
(d) n¼ 9 females and 11 males. In all graphs, *P< 0.05, **P< 0.005 and ***P< 0.001 compaStatistical analyses
Data sets did not signiﬁcantly deviate from assumptions of
normality and homoscedasticity (not shown), and so parametric
analyses were performed. Time-course data were analyzed by
repeated measures analysis of variance (ANOVA), followed where
appropriate by posthoc testing using Dunnett’s case-comparison
test (comparing postoperative time points to BL). Percent allodynia
or anti-allodynia data were analyzed by t-tests comparing drug
group or genotype. In all cases, a criterion a¼ 0.05 was adopted.
Sample sizes are provided in the ﬁgure legends.Results
DMM surgery in CD-1 mice results in chronic progressive
mechanical allodynia
BL von Frey testing occurred twice, 1 week apart, but no
repeated measures effects or interactions were noted, so for ease of
analysis and presentation these BL data were averaged. Relative to
averaged BL values, DMM surgery produced signiﬁcant, progressive
and robust (almost 50%) decreases in withdrawal thresholds in the
ipsilateral hind paws (repeated measures ANOVA: F4,72¼ 5.0,
P< 0.001) [Fig. 2(a)]. Progressive mechanical allodynia also devel-
oped in contralateral hind paws (repeated measures ANOVA:
F4,72¼ 4.9, P< 0.005) [Fig. 2(b)]. In both cases, signiﬁcant decreases
were observed on postoperative day 28 and thereafter [Fig. 2(a, b)],
although for the ipsilateral, but not contralateral hind paw the
decrease trended towards signiﬁcance as early as day 14 (P¼ 0.12).
Repeated measures ANOVAs revealed signiﬁcant changes from BL
thresholds in sham-operatedmice as well, again in both hind paws,
but this was due to signiﬁcant increases in threshold on day 14 on
the ipsilateral and on day 28 on the contralateral hind paw
[Fig. 2(c)] (ipsilateral: F4,40¼ 3.2, P< 0.05; contralateral: F4,40¼ 3.4,
P< 0.05). There was no statistical evidence of allodynia (i.e.,
decreased thresholds) in sham-operated mice at any time point.
In these young adult CD-1 mice, there was no statistical
evidence of an interaction between sex and mechanical allodynia
development (sex repeated measure: F4,68¼ 0.7, P¼ 0.58),
although in males allodynia was statistically evident on post-
operative day 14, whereas in females this was not the case until day
28 [Fig. 2(d)]. In order to conﬁrm that CD-1 mice develop OA
after DMM surgery, mice (5/sex) were euthanized on day 56 for
histological processing of the knees. It was found that both male
and female CD-1 mice had OA-like lesions, and the pathology
was similar to what has been reported for other murineerials and Methods. (a, b) n¼ 20 mice of both genders; (c) n¼ 11 mice of both sexes;
red to BL (day 0).
Fig. 3. Toluidine blue staining of a representative female (L) and male (R) knee joint in CD-1 mice, 56 days after DMM surgery (magniﬁcation 10). Note the extensive loss of
aggrecan in the medial tibial plateau, with overt lesion formation and ﬁbrillation of the articular cartilage (arrows pointing at lesion).
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in Fig. 3(a, b).
Speciﬁcity of the observed changes
No signiﬁcant changes in mechanical withdrawal threshold of
the tail were seen in mice after DMM [Fig. 4(a)], nor in their latency
to withdraw from a noxious thermal stimulus [Fig. 4(b)], with the
exception of a signiﬁcant increase in withdrawal latency of the
contralateral hind paw on day 42 (P< 0.05).
Possible confounds of von Frey testing include changes in
activity and/or motoric ability. DMM surgery did not alter overnight
home cage locomotor activity at any post-surgery time point,
although testing was sensitive enough to reveal a robust and well-
known29 difference in activity between sexes [Fig. 4(c)]. Neither
was there evidence that DMM affected gross motor functioning up
to 56 days post-surgery, since mice displayed undiminished
performance on the rotarod test (not shown).
One might expect development of knee OA to produce changes
in weight bearing. Using a particularly sensitive method of
measuring dynamic weight bearing (i.e., gait), the CatWalk system,
we could detect no evidence of gait impairment in any paw through
day 42 [Fig. 4(d)]. Unfortunately, the system malfunctioned on day
56 and no data could be collected.
Reversal of DMM-induced allodynia by analgesics
A new set of male CD-1 mice was tested for BL withdrawal
thresholds and underwent surgeries. On postoperative day 14, weFig. 4. (a) Mechanical sensitivity was measured in the tail of n¼ 11 mice of both sexes; (b)
sexes; (d) n¼ 11 mice of both sexes. *P< 0.05 compared to BL (day 0).found robust ipsilateral allodynia in these subjects (all P-values
<0.001) [Fig. 5(a, b)]. Immediately thereafter, we administered
either 10 mg/kg morphine SC, 250 mg/kg acetaminophen SC, or
their respective vehicles, and retested 30 min later. Morphine but
not saline produced a robust anti-allodynic effect (P< 0.001
compared to day 14 pre-injection ‘‘BL’’) [Fig. 5(a)]. Since morphine
produces frank analgesia in addition to anti-allodynia, we tested
a separate cohort of unoperated mice at the same time, and found
no evidence of elevation of withdrawal thresholds by morphine at
this dose [Fig. 5(a)]. Similarly, acetaminophen but not vehicle
produced signiﬁcant anti-allodynia (P< 0.05 compared to day 14
pre-injection ‘‘BL’’) [Fig. 5(b)]. No frank analgesia against mechan-
ical thresholds would be expected of acetaminophen. Both data sets
were expressed as percentage anti-allodynia, calculated for each
mouse as: [(day 14 post-injection (PI) day 14 pre-injection)/(day
0 BL day 14 pre-injection)] 100. The morphine and acetamin-
ophen doses used produced a 60% (P< 0.001 compared to saline)
and 49% (P¼ 0.12 compared to vehicle) reversal of DMM-induced
mechanical allodynia [Fig. 5(c)].
Decreased mechanical allodynia after DMM in ADAMTS-5 KO mice
In preparation for studies in Adamts5 KO mice, which are in
a C57BL/6 background,WT C57BL/6 mice were subjected to surgery
and tested for allodynia. Like CD-1, WT C57BL/6 mice displayed
progressive development of mechanical allodynia after DMM. The
expression differed from that of CD-1 mice, however, in that it was
considerably stronger in the ipsilateral [Fig. 6(a)] vs the contralateral
paw [Fig. 6(b)], and signiﬁcant in male [Fig. 6(a)] but not femaleThermal sensitivity was measured in n¼ 8 mice of both sexes; (c) n¼ 10 mice of both
Fig. 5. (a, b) Mechanical sensitivity was tested at BL and PI of either morphine or
acetaminophen. DMMþ saline, n¼ 5 mice; DMMþmorphine, n¼ 6; morphine only,
n¼ 5; DMMþ vehicle, n¼ 5; DMMþ acetaminophen, n¼ 6. (c) Data sets expressed as
% anti-allodynia. *P< 0.05, ***P< 0.001 compared to same-condition BL (in graphs a, b)
or compared to saline group (in graph c).
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separately on each hind paw and sex revealed a signiﬁcant effect of
repeatedmeasure only inmaleWTmice on the ipsilateral hind paw
(F4,40¼ 5.4, P< 0.001); in all other cases no signiﬁcant repeatedFig. 6. Withdrawal thresholds in the hind paw, measured by von Frey as described in Mater
WT and 14 KO; (b) 11 WT and 14 KO mice; (c) 13 WT and 15 KO mice; (d) 13 WT and 15 KO
possible allodynia over the entire 56-day time period, using the area over the threshold-ti
compared to WT – male group in graph e.measure was observed. Next, Adamts5 KO mice of both genders
were tested for mechanical allodynia [Fig. 6(a–d)]. BL measure-
mentswere not different from those inWTmice. After surgery,male
Adamts5 KO mice developed less allodynia than WT mice [Fig. 6(a,
b)]. Female mice did not exhibit any signiﬁcant allodynia in either
hind paw after surgery, and no genotype differences were seen
[Fig. 6(c, d)]. Data were converted to percentage of maximum
possible allodynia over the entire 56-day time course, using the area
over the threshold-time curve for each subject [Fig. 6(e)]. Signiﬁcant
genotype differenceswere observed betweenmaleWTand KOmice
for both ipsilateral and contralateral allodynia (P’s< 0.05).
Histological examination at day 14, 28, and 56 conﬁrmed that
male WT C57BL/6 mice in these studies developed typical
DMM-induced lesions, while female WT mice and Adamts5 null
mice of both genders did not develop overt lesions, as has been
described before8,30 (data not shown).
Discussion
The current work describes rapid onset of progressive bilateral
mechanical allodynia in mice undergoing DMM. The allodynia was
responsive to morphine, and somewhat less to acetaminophen,
providing empirical validity to the model. Adamts5 KOmice did not
develop mechanical allodynia after DMM surgery, consistent with
the observation that they do not develop overt OA-like joint
pathology8.
Mechanical allodynia was observed in the footpad, thus it was
secondary as opposed to primary hypersensitivity, and was present
both on the ipsilateral and contralateral side in CD-1 (but not
C57BL/6) mice. Human OA pain is mainly localized in or near the
affected joint, but referred pain and tenderness have been reported.ials and Methods. Full black line¼WT mice and dashed line¼ Adamts5 KO mice. (a) 11
mice; (e) 11 WT and 15 KO mice; (e) Data were converted to percentage of maximum
me curve for each subject. *P< 0.05, **P< 0.01 compared to BL (day 0) in graph a, or
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has been described in affected and remote joints. For example,
Kosek and Ordeberg31 described that patients with unilateral hip
OA had decreased pain thresholds for pressure stimulation in the
affected hip as well as in the contralateral normal hip, and
mechanical allodynia has been reported in knee OA32. Bradley
et al.33 reviewed evidence that, similar to ﬁbromyalgia patients,
patients with knee or hip OA exhibit abnormal pain sensitivity at
anatomic sites distal to the affected joints. Muscle hyperalgesia can
also be associated with symptomatic OA34. All this suggests that
central modulation may contribute to nociception in OA. This is
supported by the observation that intra-articular injection of a local
anesthetic in one knee can alleviate pain in the contralateral
knee35. Pain or hypersensitivity on the side of the body contralat-
eral to the injury, known as ‘‘mirror pain’’, is in fact quite well
known albeit poorly understood36. The fact that CD-1 but not
C57BL/6 mice display contralateral allodynia is also not surprising;
in a recent survey of 22 inbred mouse strains given neuropathic
spared nerve injuries, nine (including C57BL/6) displayed signiﬁ-
cant contralateral allodynia whereas the others displayed either no
changes or signiﬁcant hypoalgesia on the contralateral hind paw
(manuscript in preparation).
An interesting ﬁnding in the present study is the apparent
interaction of the precise manifestation of OA changes in this model
with sex and genotype. Sex-genotype interactions are already well
known in pain research37–39. To wit, in CD-1 mice, mechanical
allodynia and histologically deﬁned OAwere present in both males
and females. In contrast, in C57BL/6 (WT) mice, signiﬁcant behav-
ioral and histological changes were seen only in males. It has been
reported for 129SvEv30 and for other backgrounds, including
C57BL/6 mice, that only male mice develop signiﬁcant OA changes
(Glasson SS, personal communication).
In the DMM model, an apparent correlation exists between
allodynia and lesion development, because mice that do not
develop signiﬁcant lesions after surgery (i.e., female C57BL/6 (WT)
mice and male Adamts5 KO mice) do not develop allodynia. Thus,
the model may provide a system to dissect pathways involved in
generation of mechanical allodynia during lesion development. It is
noteworthy that allodynia becomes apparent as early as 14 days
after surgery, at which time the only histological changes are a mild
loss of aggrecan from the articular cartilage17 (and data not shown).
This will allow for testing the hypothesis that OA pain results
speciﬁcally from alterations in the abundance and location of
ADAMTS-5-generated fragments of its hyalectan substrates
(aggrecan, versican, and brevican), which are present in the joint.
Joint tissues that contain peripheral neurite extensions (sub-
chondral bone, synovial membrane, periosteum) all undergo
matrix remodeling during OA progression, and are exposed to
matrix, including ﬁbronectin, proteoglycan, and collagen frag-
ments. Moreover, the cells of affected joint tissues feature increased
ADAMTS-4/5 activity, resulting in the enhanced hyalectan prote-
olysis that is associated with human OA initiation and progression.
There is emerging evidence for the modifying effects of hyalectans
and their fragments on neurite extension and glial activation40,41,
a process which may be involved in pain pathogenesis42. Thus,
ADAMTS-5-mediated degradation of perineuronal hyalectans may
contribute to neuronal activation and signal transmission both in
the joint and in affected dorsal root ganglia leading to pain gener-
ation, a hypothesis which can be tested in this model through the
use of aggrecanase-inhibitors and Adamts5 KO mice.
No other potentially pain-relevant parameters, such as thermal
hyperalgesia and gait changes, were observed in the current study.
Recent work by Inglis et al. studied pain in the later stages of
murine DMM17: no changes in weight distribution were observed
during the ﬁrst 10 weeks after surgery. From 10 to 16 weeks,however, a progressive change in weight distribution occurred in
all operated mice. Likewise, changes in spontaneous activity were
not apparent until 8 weeks after surgery, at which time the authors
noted a decrease in climbing and locomotion, an increase in
immobility, and a decrease in total distance traveled during a 3-h
observation period17. Although these parameters (weight bearing,
locomotor activity) have been shown by this group to be responsive
to normalization by opioids and NSAIDs, their use as dependent
measures of pain severity is in fact quite controversial among pain
researchers14. Both weight bearing and locomotor behavior might
be independently affected by the injury as well as the pain, and
apparent analgesic effects might be secondary to drug actions
resulting in disease modiﬁcation.
There is no doubt that OA features spontaneous pain, and that
spontaneous pain is in general a higher-priority symptom to study
in pain research than mechanical allodynia43. However, secondary
mechanical allodynia – with its association to histological changes
shown herein – may nonetheless accurately predict eventual pain
levels in the DMM model, and provide a reliable (and straightfor-
ward) ‘‘read out’’ of considerable practical importance, since
signiﬁcant changes occur in 2–4 weeks instead of 8–16 weeks.
Mechanical allodynia has also been observed in rat models of
OA15,16,44, although allodynia after MMT does not occur in 100%
of rats16. A recent paper studied MIA injection into the knees of
C57BL/6mice and found that this also leads tomechanical allodynia
up to 28 days after injection45. The DMM model offers the added
advantage that, due to its protracted nature, it may provide
a system to study the pathways by which the allodynia, observed
during the ﬁrst 8 weeks after surgery, eventually progresses to
primary pain behavior, such as changes in spontaneous activity
described by Inglis et al. after 10 weeks17. The availability of
genetically modiﬁed mice will enable further research into the
mechanisms by which DMM leads to pain.
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